145 patents currently held

39 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in May 2027. from the record

Of the 39 now held by other companies, 28 name Sanofi as their current owner, and 11 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

May 2027

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 204320442045

notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Immunoglobulin Variable Domains US 11,708,404

Cited by 7 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.

Ends May 2035 · High confidence Also notable

Polypeptides and Polypeptide Constructs Comprising Single Domain Antibodies Directed Against Von Willebrand Factor US 9,028,816

Cited by 30 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.

Ends May 2027 · High confidence Also notable

Polypeptides That Modulate the Interaction Between Cells of the Immune System US 8,907,065

Cited by 42 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.

Ends Sep 2031 · High confidence

Formerly held, still cited

Notable

Immunoglobulin Variable Domains US 11,312,764

Cited by 16 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.

now held by Sanofi

Ends May 2035 · High confidence

Also notable

Techniques for Predicting, Detecting and Reducing Aspecific Protein Interference in Assays Involving Immunoglobulin Single Variable Domains US 11,644,471

Cited by 9 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.

now held by Sanofi

Ends Sep 2031 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 25, 2027
The maintenance fee for Immunoglobulin Variable Domains (US 11,708,404) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
2 fees due Feb 20 to 27, 2027 · next Feb 20
1 fee due Mar 8, 2027
The maintenance fee for Methods of Treatment Using Chemokine Receptor Binding Polypeptides (US 9,127,067) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
2 fees due Apr 6 to 13, 2027 · next Apr 6
3 fees due May 10 to 24, 2027 · next May 10
5 fees due Jun 12 to 26, 2027 · next Jun 12
1 fee due Jul 2, 2027
The maintenance fee for Amino Acid Sequences That Modulate the Interaction Between Cells of the Immune System (US 11,858,997) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
5 fees due Aug 4 to 23, 2027 · next Aug 4
4 fees due Sep 1 to 24, 2027 · next Sep 1
1 fee due Oct 14, 2027
The maintenance fee for Nanobody Against IL-6R (US 10,618,964) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

3 of the patents on this record were granted since Aug 17, 2026

What they patent

The 5 largest of its 79 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

CX3CR1-BINDING Polypeptides Comprising Immunoglobulin Single Variable Domains	6 in force	to Aug 2033
Polypeptides That Modulate the Interaction Between Cells of the Immune System	5 in force	to Sep 2031
INTERLEUKIN-6 Receptor Binding Polypeptides	5 in force	to Aug 2030
ANTI-IL-6R Polypeptides and Pharmaceutical Compositions Thereof	5 in force	to Apr 2030
Immunoglobulin Variable Domains	4 in force	to May 2035

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 9,028,816	Polypeptides and Polypeptide Constructs Comprising Single Domain Antibodies Directed Against Von Willebrand Factor In force Term ends May 22, 2027 · High confidence	In force	Term ends May 22, 2027	High confidence
US 10,618,966	Methods for the Treatment of INTERLEUKIN-6 Receptor-Related Diseases and Disorders In force Term ends Aug 17, 2027 · High confidence	In force	Term ends Aug 17, 2027	High confidence
US 7,939,277	Methods and Assays for Distinguishing Between Different Forms of Diseases and Disorders Characterized by Thrombocytopenia And/Or by Spontaneous Interaction Between Von Willebrand Factor (VWF) and Platelets In force Term ends Sep 18, 2027 · High confidence	In force	Term ends Sep 18, 2027	High confidence
US 9,617,341	Methods for Blocking or Reducing Binding of INTERLEUKIN-6 to INTERLEUKIN-6 Receptor In force Term ends Oct 29, 2027 · High confidence	In force	Term ends Oct 29, 2027	High confidence
US 9,611,326	INTERLEUKIN-6 Receptor Binding Polypeptides In force Term ends Nov 21, 2027 · High confidence	In force	Term ends Nov 21, 2027	High confidence
US 9,605,072	Nucleic Acids That Encode INTERLEUKIN-6 Receptor Binding Polypeptides In force Term ends Dec 1, 2027 · High confidence	In force	Term ends Dec 1, 2027	High confidence
US 10,844,123	Amino Acid Sequences That Modulate the Interaction Between Cells of the Immune System In force Term ends Dec 17, 2027 · High confidence	In force	Term ends Dec 17, 2027	High confidence
US 9,512,236	Amino Acid Sequences Directed Against Gpcrs and Polypeptides Comprising the Same for the Treatment of Gpcr-Related Diseases and Disorders In force Term ends Dec 19, 2027 · High confidence	In force	Term ends Dec 19, 2027	High confidence
US 10,208,115	Amino Acid Sequences That Modulate the Interaction Between Cells of the Immune System In force Term ends Aug 13, 2028 · High confidence	In force	Term ends Aug 13, 2028	High confidence
US 10,087,251	Amino Acid Sequences That Modulate the Interaction Between Cells of the Immune System In force Term ends Sep 4, 2028 · High confidence	In force	Term ends Sep 4, 2028	High confidence

10 of 145 patents shown.

Pro members see all 145.

Pro members: see all 145 patents

Also on record, not counted in the 145: 39 patents in force now held by others · 17 patents ended · 50 applications pending · 90 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Ablynx N.V.